KK
DNLI icon

KLP Kapitalforvaltning’s Denali Therapeutics DNLI Stock Holding History

KLP Kapitalforvaltning’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$795K Hold
30,900
– – ﹤0.01% 1259
2026
Q1 		$593K Buy
30,900
+1,000
+3% +$19.9K ﹤0.01% 1345
2025
Q4 		$494K Hold
29,900
– – ﹤0.01% 1423
2025
Q3 		$434K Buy
29,900
+3,800
+15% +$54.6K ﹤0.01% 1471
2025
Q2 		$365K Hold
26,100
– – ﹤0.01% 1504
2025
Q1 		$355K Hold
26,100
– – ﹤0.01% 1483
2024
Q4 		$532K Buy
+26,100
New +$668K ﹤0.01% 1341

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KLP Kapitalforvaltning's DNLI Position: Q2 2026 in Review

KLP Kapitalforvaltning held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 30,900 shares worth $795K. The position accounts for ﹤0.01% of the portfolio, ranked #1259.

KLP Kapitalforvaltning first reported a position in DNLI in Q4 2024 and has held it in 7 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • KLP Kapitalforvaltning held 30,900 shares of Denali Therapeutics worth $795K as of Q2 2026.
  • KLP Kapitalforvaltning left its Denali Therapeutics share count unchanged in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1259 holding.
  • KLP Kapitalforvaltning first reported a position in Denali Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.